All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
Despite the use of prophylactic measures, graft-versus-host disease (GvHD) remains an ongoing complication for ~30–50% patients following allogeneic hematopoietic stem cell transplantation. Extracorporeal photopheresis (ECP) has been investigated for the treatment of acute and chronic GvHD, both as monotherapy and in combination with other agents, due to its immunomodulatory and steroid-sparing efficacy. It is typically considered as a second-line or later treatment option for patients with acute or chronic GvHD who are steroid-refractory.
In this e-learning module, we describe the current unmet needs and challenges in GvHD – including the side effects associated with prolonged steroid use and the management of steroid- and treatment-refractory disease – and the rationale for the use of ECP in the treatment of GvHD. We then go on to summarize clinical data supporting ECP therapy for GvHD and best practice recommendations for its use, and we explore patient selection and treatment sequencing with ECP through guided case studies.
In the first chapter of this e-learning module, we describe the current unmet needs and challenges in acute and chronic graft-versus-host disease (GvHD), and we introduce the mechanism of action of extracorporeal photopheresis (ECP) and the rationale for its use in the treatment of GvHD.
In the second chapter of this e-learning module, we present clinical data supporting the use of extracorporeal photopheresis (ECP), either alone or in combination with other agents, in the treatment of graft-versus-host disease (GvHD).
In the third chapter of this e-learning module, we describe the current guidelines and latest recommendations from expert groups for the use of extracorporeal photopheresis (ECP) in the treatment of acute and chronic graft-versus-host disease (GvHD).
In the fourth chapter of this e-learning module, we present two patient case studies navigating the graft-versus-host disease (GvHD) treatment journey, including patient selection and treatment sequencing with extracorporeal photopheresis (ECP).
This educational resource is independently supported by Therakos. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Your opinion matters
Which consideration most strongly guides your decision to escalate therapy in SR-aGvHD?
.webp&w=3840&q=75)
